• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

肾素系统与高血压并发症及其治疗的新认识。

The renin system and new understanding of the complications of hypertension and their treatment.

作者信息

Laragh J H

机构信息

Cardiovascular Center, New York Hospital, Cornell Medical Center, New York.

出版信息

Arzneimittelforschung. 1993 Feb;43(2A):247-54.

PMID:8498972
Abstract

The renin-angiotensin-aldosterone hormonal axis is the major long-term servocontrol for regulation of both arterial blood pressure and sodium balance. It supports normotension or hypertension via angiotensin vasoconstriction and angiotensin plus aldosterone-induced renal sodium retention. Normally, in the presence of hypertension or sodium-volume excess, plasma renin activity promptly falls to zero. Accordingly, any renal secretion of renin in the face of high blood pressure is abnormal. In established essential hypertension varying degrees of abnormal plasma renin activity operate to cause or sustain the hypertension; only very low plasma renin values reflect a normal renal response. Human hypertensive disorders comprise a spectrum of abnormal plasma renin-sodium volume products. High renin, intensely vasoconstricted, hypovolemic forms (e.g., malignant, renovascular) are one extreme of the spectrum; "wet"-volume-excess low-renin forms are the other extreme (e.g., primary aldosteronism, low-renin essential hypertension). These varying, but abnormal renin-sodium products are caused by a renal lesion in which a subpopulation of ischemic nephrons hypersecretes renin and retains sodium despite systemic hypertension and sodium excess. Thus, hypertensive patients cannot suppress their renin secretion normally. The hypertension from this renal lesion is correctable by agents that reduce renin secretion or block its effect (beta blockade, CEI, renin inhibition, or angiotensin II antagonism). None of these agents lower blood pressure after binephrectomy, verifying the renal origin of renin in the cardiovascular control system. In essential hypertension, the plasma renin level appears as a continuous variable associated with greater risk of ischemic injury.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

肾素-血管紧张素-醛固酮激素轴是调节动脉血压和钠平衡的主要长期伺服控制系统。它通过血管紧张素收缩血管以及血管紧张素和醛固酮诱导的肾脏钠潴留来维持正常血压或高血压。通常,在高血压或钠容量过多的情况下,血浆肾素活性会迅速降至零。因此,在高血压情况下肾脏分泌任何肾素都是异常的。在已确诊的原发性高血压中,不同程度的异常血浆肾素活性会导致或维持高血压;只有极低的血浆肾素值才反映正常的肾脏反应。人类高血压疾病包括一系列异常的血浆肾素-钠容量产物。高肾素、强烈血管收缩、低血容量型(如恶性、肾血管性)是该谱系的一端;“湿”容量过多的低肾素型是另一端(如原发性醛固酮增多症、低肾素原发性高血压)。这些不同但异常的肾素-钠产物是由肾脏病变引起的,在这种病变中,尽管存在全身性高血压和钠过多,但局部缺血性肾单位亚群会过度分泌肾素并潴留钠。因此,高血压患者不能正常抑制其肾素分泌。这种肾脏病变引起的高血压可通过降低肾素分泌或阻断其作用的药物(β受体阻滞剂、CEI、肾素抑制或血管紧张素II拮抗)来纠正。双侧肾切除术后,这些药物均不能降低血压,这证实了肾素在心血管控制系统中的肾脏起源。在原发性高血压中,血浆肾素水平表现为一个连续变量,与缺血性损伤风险增加相关。(摘要截选至250字)

相似文献

1
The renin system and new understanding of the complications of hypertension and their treatment.肾素系统与高血压并发症及其治疗的新认识。
Arzneimittelforschung. 1993 Feb;43(2A):247-54.
2
Recognizing and treating two types of long-term vasoconstriction in hypertension.认识并治疗高血压中的两种长期血管收缩类型。
Kidney Int Suppl. 1988 Sep;25:S162-74.
3
Renin-angiotensin-aldosterone system for blood pressure and electrolyte homeostasis and its involvement in hypertension, in congestive heart failure and in associated cardiovascular damage (myocardial infarction and stroke).肾素-血管紧张素-醛固酮系统对血压和电解质平衡的作用及其在高血压、充血性心力衰竭以及相关心血管损伤(心肌梗死和中风)中的作用。
J Hum Hypertens. 1995 Jun;9(6):385-90.
4
Lewis K. Dahl Memorial Lecture. The renin system and four lines fo hypertension research. Nephron heterogeneity, the calcium connection, the prorenin vasodilator limb, and plasma renin and heart attack.刘易斯·K·达尔纪念讲座。肾素系统与四条高血压研究路线。肾单位异质性、钙的关联、前肾素血管舒张分支以及血浆肾素与心脏病发作。
Hypertension. 1992 Sep;20(3):267-79. doi: 10.1161/01.hyp.20.3.267.
5
New concepts of the renin system and of vasoconstriction-volume mechanisms. Diagnosis and treatment of renovascular and renal hypertensions.肾素系统及血管收缩-容量机制的新概念。肾血管性高血压和肾性高血压的诊断与治疗。
Urol Clin North Am. 1975 Jun;2(2):237-57.
6
Converting enzyme inhibition to identify and treat renin-mediated or sodium-volume related forms of increased peripheral resistance in hypertension and in congestive heart failure.通过转换酶抑制作用来识别和治疗高血压及充血性心力衰竭中由肾素介导或与钠容量相关的外周阻力增加形式。
J Hypertens Suppl. 1983 Oct;1(1):77-84.
7
Discordant nephron function. A pathogenic factor in hypertension and its vascular complications of stroke and heart attack.
Am J Hypertens. 1991 Jan;4(1 Pt 2):2S-6S.
8
[Arterial hypertension in patients on chronic hemodialysis].[慢性血液透析患者的动脉高血压]
Srp Arh Celok Lek. 1996 Sep-Oct;124(9-10):246-50.
9
Renal mechanisms of angiotensin II-induced hypertension.血管紧张素II所致高血压的肾脏机制
Semin Nephrol. 2000 Sep;20(5):417-25.
10
The renin-angiotensin system and hypertension.
Clin Exp Pharmacol Physiol Suppl. 1982;7:31-40.

引用本文的文献

1
Omapatrilat provides long-term control of hypertension: a randomized trial of treatment withdrawal.奥马曲拉可长期控制高血压:一项撤药随机试验
J Clin Hypertens (Greenwich). 2002 May-Jun;4(3):169-72. doi: 10.1111/j.1524-6175.2002.01400.x.
2
A double-blind, placebo-controlled study to assess tolerability, pharmacokinetics and preliminary pharmacodynamics of single escalating doses of Z13752A, a novel dual inhibitor of the metalloproteases ACE and NEP, in healthy volunteers.一项双盲、安慰剂对照研究,旨在评估新型金属蛋白酶ACE和NEP双重抑制剂Z13752A在健康志愿者中单次递增剂量给药后的耐受性、药代动力学和初步药效学。
Br J Clin Pharmacol. 2000 Oct;50(4):338-49. doi: 10.1046/j.1365-2125.2000.00257.x.